Take a Bite
As soon as the chart window popped open, I quickly pulled up Velmira Biopharma's order book.
Velmira Biopharma
Tick. Tick. Tick.
Even in that brief moment I spent staring at the order book, Velmira Biopharma's stock price was wriggling around like a living thing.
"Ughhh. Already a bit late."
Velmira Biopharma: +7.1%
Obvious as it might sound, I'm no god.
Just a guy who made a name for himself on Wall Street.
And since I'm no god, it's impossible to buy every stock at the absolute bottom and sell at the peak every time.
"But who the hell doesn't know that when it comes to investing in stocks?"
That's why retail investors... or ants, as we call them, jump in once the stock starts rising.
News packed with good vibes, community posts bragging about profits, target prices from Wall Street IB analysts...
The ants see that stuff forecasting a bright future and cling to the hope it'll keep going up. Hell, some even go all-in with their life savings based on it.
But truth is, the news and those Wall Street analyst target prices are just the results of stuff that's already happened.
News drops after the good news is already baked into the price.
In other words, the people who matter already started buying.
"Sure, tough for retail to get that info first."
Think of it like a movie trailer. Do they shoot the trailer first and then make the movie to match?
"Hell no."
Trailers come after filming and editing, just to hype people up. Wall Street's the same.
You don't throw big money around without a plan. And most of that money already has its direction set.
And target prices? Just tools to justify that direction.
Bet the farm on that alone?
Even the craziest bastards wouldn't risk their own cash like that... or maybe they do. Impressive in a dumb way. Classic case of ignorance being bliss.
Not that it's bad. I need people who'll jump into the fire with their own money.
Those are the ones who'll follow me no matter how weird my moves or strategies seem—prime suckers, er, investors.
Wall Street whales nag their funds if the risk looks too high. "Trim the position?" Turns to threats of redemptions if you don't budge.
Partly the scale, sure, but mindset too. Big money means establishment. Old money families obsess over protecting what they have, not chasing new gains.
Old money sounds all aristocratic and fancy...
Trace the lineage, and it's mostly slave plantation owners. Labor? Whip the natives. Output? More land. Demand? Europe buys it all.
Zero risk, compound gains.
"And like I said before, money breeds money."
Farm booms, capital overflows? Buy railroads, real estate—that's old money's origin.
And those create influence.
Say city A has rail, B doesn't. Businesses flock to A for cheap logistics. Jobs follow. Why would capital go to B?
Real estate's obvious. Hard-to-replace assets just appreciate more over time.
Old money's like an idle game. Why risk when it grows on autopilot?
Ants are different. No elite networks, family rep, or fortunes to lose. More precisely...
They already feel like life's lost. So they don't need genius strategies or big brains—just a beacon to follow.
"Chased credible news and targets so far, but..."
Ants want profits. Give 'em certainty it'll print money if they follow, and they'll ditch credibility for returns.
"Me, that is."
I shrugged at the massive sell wall—way bigger than the price rise warranted. Maybe that's why Velmira Biopharma's insane surge was fizzling out.
Velmira Biopharma. Sounds like your average small-cap biotech.
"Market cap under a trillion won... chronic losses."
But if it were truly trash, acquisition candidates wouldn't be baring teeth over it. Competition means value.
"One standout: this."
AbsoluteDefense / VB-271: Phase 2 Interim Results
One drug in Phase 2 trials. That's basically all Velmira has.
But its value? Like red beans plus shaved ice in a red bean shaved ice bowl. No beans or ice? Not the dish.
Meaning that drug is the whole damn thing.
Gaudy name: AbsoluteDefense. Matches the hype—VB-271's expected effects are huge.
I'm no biotech whiz, but I get the value.
Immunosuppressants blanket-suppress immunity. VB-271 targets just the problem parts.
Strong drugs are risky, safe ones weak—duh. But VB-271 nails both.
Keeps effects, cuts side effects. If true, paradigm-shattering.
Analysts' reports? They'd call way higher than that.
Acquirers fear not failure—success. Phase 3 pass? Superior to all existing immunosuppressants. Market monopoly obvious.
"Miss it, and rivals eat you alive. Hence the bloodshot eyes."
Forced into the auction 'cause success scares more than failure...
But wait, doesn't that feel off?
Only +7% on that news? Wall Street wouldn't miss this. Sell wall huge, but price holds? Weird.
"Aha. The M&A players already threw down."
Big sell wall, price steady? Someone's eating all the supply below.
Not for defense—bluffing.
"Scare tactic."
Fake fear, suppress price, scoop shares. Who else at this stage?
One of the acquirers, duh.
Explains the earlier surge too.
Another acquirer countering.
One scoops cheap to gain auction edge. Rival pumps buys to fight back. Hence the volume—too big for ants.
"No wonder the trades were whale-sized."
Ants fled the whale fight, spooked.
But this has to moon. Unless the tech's fake—and if so, why fight? Greedy bastards.
"C'mon, let's eat together. Yeah?"
Deciding to "take a bite" on the acquirers myself, I headed straight to the gallery.
Aw, but our house has a big family, see.
Let's eat together?